1195765-45-7 | Dabrafenib

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
250mg	98%	in stock	$61.00	$43.00
1g	98%	in stock	$152.00	$106.00

Description

• Catalog Number: AA24379
• Chemical Name: Dabrafenib
• CAS Number: 1195765-45-7
• Molecular Formula: C23H20F3N5O2S2
• Molecular Weight: 519.5624
• MDL Number: MFCD17215684
• SMILES: Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C

Computed Properties

• Complexity: 817
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 6
• XLogP3: 4.8

Literature

• Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.

  Chemico-biological interactions 20171225

• Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption.

  Chemico-biological interactions 20160825

• Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

  British journal of cancer 20160315

• Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.

  Scientific reports 20160101

• Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

  Expert opinion on drug metabolism & toxicology 20130701

• BRAF inhibitor activity in V600R metastatic melanoma.

  European journal of cancer (Oxford, England : 1990) 20130301

• BRAF inhibition and beyond in advanced melanoma.

  Lancet (London, England) 20120728

• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  Lancet (London, England) 20120728

• Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.

  Archives of dermatology 20120301

• Small molecule inhibitors of BRAF in clinical trials.

  Bioorganic & medicinal chemistry letters 20120115

• Overcoming metastatic melanoma with BRAF inhibitors.

  Archives of pharmacal research 20110501

• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

  Nature 20100930